Clinical Trials | September 03, 2024
Tolebrutinib meets primary endpoint in HERCULES phase 3 study
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Phase 3 study results will form the basis for future discussions with global regulatory authorities
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer’s fully integrated $20 billion healthcare business
Subscribe To Our Newsletter & Stay Updated
